[
  {
    "ts": "2025-07-31T20:30:00+00:00",
    "headline": "Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI速 (tafasitamab) for Follicular Lymphoma in Brazil",
    "summary": "MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI速 (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular",
    "url": "https://finance.yahoo.com/news/knight-therapeutics-announces-regulatory-supplemental-203000853.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "2cb25e34-ac20-3073-a3ee-b146fc69b978",
      "content": {
        "id": "2cb25e34-ac20-3073-a3ee-b146fc69b978",
        "contentType": "STORY",
        "title": "Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI速 (tafasitamab) for Follicular Lymphoma in Brazil",
        "description": "",
        "summary": "MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI速 (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular",
        "pubDate": "2025-07-31T20:30:00Z",
        "displayTime": "2025-07-31T20:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/6f19f960aa8749173a3ec6cb85899dea",
          "originalWidth": 982,
          "originalHeight": 257,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ssoKuPl1bS.IGmti1_Z9Yg--~B/aD0yNTc7dz05ODI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6f19f960aa8749173a3ec6cb85899dea.cf.webp",
              "width": 982,
              "height": 257,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ANVSHUd_Hgv99ClTKZZAfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/6f19f960aa8749173a3ec6cb85899dea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/knight-therapeutics-announces-regulatory-supplemental-203000853.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/knight-therapeutics-announces-regulatory-supplemental-203000853.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KHTRF"
            },
            {
              "symbol": "GUD.TO"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]